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Abstract
Background: To date, there are no clinically reliable predictive markers of response to the current treatment
regimens for advanced colorectal cancer. The aim of the current study was to compare and assess the power of
transcriptional profiling using a generic microarray and a disease-specific transcriptome-based microarray. We also
examined the biological and clinical relevance of the disease-specific transcriptome.
Methods: DNA microarray profiling was carried out on isogenic sensitive and 5-FU-resistant HCT116 colorectal
cancer cell lines using the Affymetrix HG-U133 Plus2.0 array and the Almac Diagnostics Colorectal cancer disease
specific Research tool. In addition, DNA microarray profiling was also carried out on pre-treatment metastatic
colorectal cancer biopsies using the colorectal cancer disease specific Research tool. The two microarray platforms
were compared based on detection of probesets and biological information.
Results: The results demonstrated that the disease-specific transcriptome-based microarray was able to out-
perform the generic genomic-based microarray on a number of levels including detection of transcripts and
pathway analysis. In addition, the disease-specific microarray contains a high percentage of antisense transcripts
and further analysis demonstrated that a number of these exist in sense:antisense pairs. Comparison between cell
line models and metastatic CRC patient biopsies further demonstrated that a number of the identified sense:
antisense pairs were also detected in CRC patient biopsies, suggesting potential clinical relevance.
Conclusions: Analysis from our in vitro and clinical experiments has demonstrated that many transcripts exist in
sense:antisense pairs including IGF2BP2, which may have a direct regulatory function in the context of colorectal
cancer. While the functional relevance of the antisense transcripts has been established by many studies, their
functional role is currently unclear; however, the numbers that have been detected by the disease-specific
microarray would suggest that they may be important regulatory transcripts. This study has demonstrated the
power of a disease-specific transcriptome-based approach and highlighted the potential novel biologically and
clinically relevant information that is gained when using such a methodology.
Background
Response rates for advanced colorectal cancer (CRC)
remain disappointingly low at 40-50% for 5-FU-based
combination therapies [1,2]. The poor response rates are
due to drug resistance, which is either inherent or
acquired in nature. A number of predictive markers of
response to these therapies have been proposed, how-
ever, the results are controversial [3-16] and to date,
outside of KRAS testing, no predictive markers have
made the transition to routine clinical use. Due to the
lack of clinical implementation of molecular markers
there is a need to identify robust predictive markers of
response to ultimately increase response rates to treat-
ment in these patients.
Many studies have identified predictive markers or
cassettes of predictive markers using gene expression
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have utilized the leading generic microarray and com-
pared it to a disease-specific transcriptome-based micro-
array. It is of interest to assess the content of the
unique information present in the disease-specific
microarray in relation to drug treatment and in the
identification of potential predictive markers in this dis-
ease setting. Recently, the ENCODE pilot project pub-
lished its findings on the detailed characterization of 1%
of the human genome [22]. The study observed a much
higher level of transcription than was originally thought
to occur including a high level of non-protein encoding
transcripts. Indeed several studies have suggested that
up to 20% of all protein-encoding genes could have an
associated natural antisense transcript (NAT) [23]. The
aim of the present study was to assess the benefit of a
disease-specific transcriptome-based profiling approach
compared to a generic genomic-based microarray. In
addition, we examined the composition of the disease-
specific transcripts and found a high level of NAT
expression both in vitro and clinically in this disease set-
t i n g .T h e s eh a v eaf u n c t i o n a lr o l ei nr e s p o n s et od r u g
treatment in colorectal cancer and warrant further
investigation.
Methods
Microarray Profiling and Experiment Design
We have previously carried out microarray profiling
experiments using HCT116 colorectal cancer cells on
the Affymetrix HGU133 Plus2.0 array (Plus2.0 array)
[24] and the Almac Diagnostics Colorectal cancer
DSA (Colorectal DSA). HCT116 parental cells and
5-FU-resistant daughter cells [25] were either
untreated (0 h control) or treated with 5 μM5 - F U
(IC50(72 h) for the parental cell line) for 24 hours
(Additional File 1A). The comparison between paren-
tal control and parental treated with 5-FU is referred
as the ‘sensitive’ experiment; while the comparison
between the resistant control and the resistant treated
with 5-FU is referred as the ‘resistant’ experiment.
Microarray profiling was carried out on 28 pre-
treatment (Irinotecan/5-FU) metastatic biopsies using
the Colorectal DSA [26]. All patients provided written
fully informed consent as per IRB guidelines in the
University of Southern California and approval was
granted from this body. These patients underwent
biopsy of colorectal liver metastases prior to commen-
cing irinotecan/5-FU chemotherapy on the IFL sche-
dule. Detailed experimental protocols and raw
expression data are available at http://www.ebi.ac.uk/
arrayexpress/ (Accession numbers E-MEXP-1691
(in vitro) and E-MEXP-1692 (Clinical) for Colorectal
DSA analysis and Accession number E-MEXP-390 for
Affymetrix Plus2.0 analysis).
Quantitative reverse transcription-PCR analysis
Total RNA was isolated using RNA STAT-60 (Tel-Test,
Inc.) according to the manufacturer’si n s t r u c t i o n s .
Reverse transcription was carried out using 2 μgo f
RNA using a Moloney murine leukemia virus-based
reverse transcriptase kit (Invitrogen) according to the
manufacturer’s instructions. Quantitative reverse tran-
scription-PCR (RT-PCR) amplification was carried out
in a final volume of 10 μL containing 5 μLo f2 × S Y B R
green master mix (Qiagen), 4 μL of primers (2 μM), and
1 μl of cDNA using an Opticon DNA Engine Thermal
Cycler (Bio-Rad Laboratories, Inc., Waltham, MA) using
methods previously described [26]. All amplifications
were primed by pairs of chemically synthesized 18- to
22-mer oligonucleotides designed using freely available
primer design software (Primer3) http://frodo.wi.mit.
edu/primer3/ (Additional file 2).
Derivation of unique microarray content lists
HG-U133 Plus2.0 full sequences and probes were down-
loaded from the Affymetrix website http://www.affyme-
trix.com/ in FASTA format. Probe and full sequences
used in the design of the Colorectal DSA were obtained
from Almac Diagnostics in FASTA format.
Probe sequences from the Colorectal DSA probesets
were aligned against the Plus2.0 array full length
sequences using BLAST [27]. Where 6 or more probes
from a probeset (usually 11 probes) aligned to the same
sequence with 100% identity over their entire length, the
DSA probeset and the Affymetrix sequence were consid-
ered ‘common’. Full length sequences representing the
DSA probesets not considered common at this stage
were extracted and the Plus2.0 array probesets were
BLASTed against them. Where 6 or more probes from a
probeset (usually 11 probes) aligned to the same
sequence with 100% identity over their entire length, the
DSA sequence and the Affymetrix probeset were again
considered ‘common’. Those sequences/probesets not
considered common at this stage also formed the
‘unique’ groupings.
Data Analysis
Data analysis was conducted using either Genespring
GX v 7.3.1 (Agilent Technologies, UK) or the R statisti-
cal package [28] and Bioconductor [29]. Background
correction, scaling and summarization of the raw data
to generate expression values were done with the MAS5
algorithm. The experiment was setup to measure the
ability of each microarray platform to detect probesets,
detect differentially expressed probesets and also to
detect biologically relevant (cancer-related) probesets.
Detection Filtering
The detection of probesets was measured based on the
MAS5 present, marginal and absent flag calls. For all
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present or marginal were counted using data from the
whole microarrays in both Plus2.0 array and Colorectal
DSA. The number of probesets consistently detected
across the 3 replicates in each condition, i.e., untreated
parental, 5-FU treated parental, untreated 5-FU resistant
and 5-FU treated 5-FU resistant, was calculated by
selecting the probesets passing the flag filter in all the 3
replicates in each case.
Differential Expression Filtering
For both the Colorectal DSA and the Plus2.0 complete
microarray data, following detection filtering, probesets
were further filtered based on fold change in expres-
sion and a statistical filter in the case of both HCT116
parental and 5-FU resistant cell line data. Differential
expression was measured between untreated and 5-FU
treated samples in both the sensitive and resistant
experiments. All probesets passing the fold change
filter of 1.3 fold and also with a t-test p-value less than
0.05 were counted for differentially expressed
transcripts.
Pathway Analysis
All pathway analysis was carried out using Genespring
v7.3.1 (Agilent Technologies, UK) using both KEGG and
GenMAPP pathways. Pathway analysis was carried out
using the complete content of each microarray platform
for those probesets that were detected (present/mar-
ginal) and differentially expressed (1.3-fold + t test) in
the sensitive and resistant experiments and pathways
were selected that contained greater than 15 genes (sen-
sitive experiment) and 10 genes (resistant experiment)
per pathway. Statistical analysis for each pathway was
carried out using hypergeometric statistics. The number
of genes per pathway cut-off was selected based on the
total number of genes contained within a given
experiment.
Analysis of sense and antisense probesets
The total number of sense and antisense transcripts in
the unique content (23,089 probesets) of the Colorectal
DSA was assessed. In addition to the Colorectal DSA-
specific probesets, the numbers of sense and antisense
probesets within this group, which were detected in the
in vitro (sensitive and resistant) and clinical experiments
were also assessed independently. Detection was deter-
mined by the present and marginal flag calls as
described earlier. Finally, probesets that passed both the
detection filter and differential expression filter were
classified into sense and antisense orientations and
counted
In all the cases above, it was further investigated to
find whether sense:antisense (SAS) pairs exist
Genomic Alignment of SAS pairs
Full sequences corresponding to the Colorectal DSA
probesets were aligned to the human genome (Ensembl
release 51.36 m; NCBI build 36) using BLAT via the
Ensembl [30] website http://www.ensembl.org/index.
html. The highest scoring alignments were viewed using
the ‘region in detail’ view of the Ensembl genome brow-
ser. Tracks were customized to include known Ensembl
genes and GENSCAN [31] predicted genes using the
‘configure this page’ option.
Clinical Analysis
All probesets from the colorectal DSA analysis of meta-
static CRC patient samples were initially filtered using
detection flag calls, with present or marginal calls in >
50% of all samples. Subsequently, probesets were filtered
using differential expression with a change of 1.5-fold in
at least one condition (CR, PR, SD and PD). Sense and
antisense probes were isolated from each list and only
the probes with associated annotation were taken for-
ward for SAS pair analysis.
Results
Comparison of the Affymetrix HGU133 Plus2.0 microarray
with the Almac Diagnostics Colorectal Cancer DSA
To assess the benefit of the Almac Diagnostics Color-
ectal Cancer Disease-Specific Array (further referred as
“Colorectal DSA”)w ec o m p a r e di td i r e c t l yt ot h eA f f y -
metrix Human Genome U133 Plus2.0 microarray
(further referred as “Plus2.0 array”). In this study, the
HCT116 colorectal cancer cell line was used along
with the 5-FU-resistant daughter cell line [25]. The
HCT116 parental (5-FU sensitive) cell line was either
untreated (control) or treated with 5 μM5 - F Uf o r
24 h, and will be referred further as the “sensitive
experiment”. The HCT116 5-FU-resistant cell line was
either untreated (control) or treated with 5 μM5 - F U
for 24 h, and will be referred as the “resistant experi-
ment”. RNA was harvested and arrayed in triplicate
(biological replicates) on either the Colorectal DSA or
t h eP l u s 2 . 0a r r a y( A d d i t i o n al File 1A). When compar-
ing the Colorectal DSA to the Plus2.0 array, the Color-
ectal DSA contained 61,528 probesets in total, with
23,089 probesets specific (unique) to the Colorectal
DSA. The Plus2.0 array contained 54,675 probesets, of
which 24,941 probesets were specific (unique) to the
Plus2.0 array (Table 1).
To compare the two microarray platforms, we com-
pared the complete content of each array based on
detection (Affymetrix MAS5 present (P) or marginal
(M) flag calls) and detection + differential expression
(1.3-fold change and t-test p-value <0.05).
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In order to validate the microarray results, we measured
the expression of a representative number of genes from
the in vitro Colorectal DSA experiment by quantitative
RT-PCR, we have previously validated the Plus2.0 array
experiment [24]. For the Colorectal DSA 13 genes
(Additional file 2) were selected for validation; all valida-
tions were carried out in three independent experiments
(Additional file 3). The genes were selected based on
fold-induction, with both highly and more moderately
induced genes chosen and both up-regulated and down-
regulated genes analyzed.
For the selected genes, the average fold-changes by
both microarray and quantitative RT-PCR were log
transformed and the correlation between the expression
values were examined using Pearson’s product correla-
tion moment (r). For the 13 genes acutely altered in the
HCT116 parental cells following 5-FU treatment over
24 h, the Pearson’s correlation (r) was 0.75, with r
2 =
0.57 (p = 0.0032). In terms of the basal alterations
between parental and 5-FU-resistant cells, Pearson’s cor-
relation (r) of the 13 genes was 0.78, with r
2 =0 . 6 1( p=
0.0017) (Additional file 3). Taken together, these results
demonstrate that there is a strong overall concordance
between the real-time PCR validation and the microar-
ray experiment. Therefore these results highlight the
robustness of the original microarray experiment.
Analysis of the total content of the microarray platforms
The total content of each microarray platform was
assessed based on detection and detection plus differen-
tial expression (Figure 1A-B). When comparing the Col-
orectal DSA to the Plus2.0 array based on detection
only, the Colorectal DSA consistently detected (in all
three replicates) a higher number of present or marginal
probesets compared to the Plus2.0 array (Figure 1A).
There was also a marked reduction in the variance
across the replicates for the colorectal DSA compared to
the Plus2.0 array suggesting a greater degree of reprodu-
cibility for the Colorectal DSA.
The complete content of each microarray was also
compared based on detection and differential expres-
sion. The colorectal DSA detected a higher number of
probesets compared to the Plus2.0 array when detection
and differential expression were taken into account. The
colorectal DSA detected 3713 differentially expressed
probesets in the sensitive and 1660 differentially
expressed probesets in the resistant experiments while
t h eP l u s 2 . 0a r r a yd e t e c t e do n l y3 2 9 6d i f f e r e n t i a l l y
expressed probesets in the sensitive and 564 differen-
tially expressed probesets in the resistant experiments
(Figure 1B). Taken together, these results suggest that
the Colorectal DSA consistently detects a higher num-
ber of differentially express e dp r o b e s e t sa n dd i s p l a y sa
lower variance between sample replicates.
Pathway analysis of the microarray platforms
To further assess the biological relevance of each micro-
array platform, we carried out pathway analysis on the
probesets that passed the detection filter, 1.3-fold
change and also t test filtering (p-value < 0.05) in the
sensitive experiment. Using all of the probesets of each
microarray as a starting point, the Plus2.0 array had
3,296 probesets that passed all three filters while the
Colorectal DSA had 3,713 probesets that passed all
three filters in the sensitive experiment. Following path-
way analysis, filtered data from the Plus2.0 array gener-
ated 10 statistically significant differentially regulated
pathways (Table 2). Starting with the filtered data from
the Colorectal DSA 16 statistically significant differen-
tially regulated pathways were identified (Table 3). Over-
all there were 7 pathways in common between the two
microarray platforms: cell cycle, folate biosynthesis, gly-
cerophospholipid metabolism, oxidative phosphorylation,
purine metabolism, pyrimidine metabolism and starch
and sucrose metabolism (Tables 2 and 3). When exam-
ining the common pathways between the two platforms
in terms of the number of probesets detected and differ-
entially expressed, the Colorectal DSA detected signifi-
cantly more probesets for 6 of the 7 pathways (Cell
cycle, Glycerophospholipid metabolism, Oxidative phos-
phorylation, Purine metabolism, Pyrimidine metabolism
and Starch and sucrose metabolism). The Plus2.0 array
only detected more probesets for one of the common
pathways (Folate biosynthesis). The pathways that were
identified by the Plus2.0 array alone were Aminoacyl-
tRNA biosynthesis, Ubiquitin-mediated proteolysis and
Wnt signaling, while the pathways identified by the Col-
orectal DSA only were Biosynthesis of steroids, DNA
polymerase, Fatty acid metabolism, Fructose and
mannose metabolism, Glycolysis and Gluconeogenesis,
Insulin signaling pathway, Proteasome, Tryptophan
metabolism and Valine, leucine and isoleucine
degradation.
We also examined which pathways were differentially
regulated in the resistant experiment between the
Plus2.0 array and the Colorectal DSA. In the resistant
experiment, following filtering (Flags, 1.3-fold and
t-test), 1660 genes were identified as altered following
Table 1 Content of Plus2.0 array and Colorectal DSA
Probesets HGU133 Plus2.0 Colorectal DSA
Total 54,675 61,528
Common 29,734 38,439
Unique 24,941 23,089
In addition to the total content of the microarrays, the number of probesets
in common, as well as, the number of Colorectal DSA-specific probesets and
Plus2.0-specific probesets are also displayed in the table.
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Page 4 of 145-FU treatment using the Colorectal DSA, while only
564 genes were identified as altered following 5-FU
treatment using the Plus2.0 array. Pathway analysis
revealed that 19 pathways were altered following 5-FU
treatment using the Colorectal DSA, while only 3 path-
ways were altered following 5-FU treatment using the
Plus2.0 array (Additional File 4). The 3 pathways (Focal
adhesion, MAPK signaling and regulation of the actin
cytoskeleton) that were identified using the Plus2.0 array
were also identified using the Colorectal DSA, therefore,
the Plus2.0 array was not identifying any unique infor-
mation. In addition, there was no overlap in the identi-
fied pathways between the sensitive and the resistant
experiments using the Plus2.0 array. Using the Colorec-
tal DSA, 16 unique pathways were identified that were
not identified by the Plus2.0 array and 4 pathways (Cell
cycle, Insulin signaling, Purine metabolism and Pyrimi-
dine metabolism) were identified in both the sensitive
and the resistant experiments (Additional File 5). These
pathways may play an important role not only in drug
A.
B.
Figure 1 Complete probeset analysis. Results from the analysis of the complete content of the Plus2.0 array and the Colorectal DSA. A. Graph
showing the number of probesets consistently detected (P or M) across all three replicates of parental untreated, parental 5-FU treated, 5-FU-
resistant untreated and 5-FU-resistant 5-FU treated. B. Graph displaying the number of probesets detected, differentially expressed (at 1.3-fold)
and passing t-test filter (p < 0.05) in the parental and 5-FU-resistant cells following 5-FU treatment.
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Page 5 of 14response, but also in drug resistance. Overall, it appears
that compared to the Plus2.0 array, the Colorectal DSA
is providing more biologically relevant information, both
in the sensitive and resistant experiments.
Composition of the specific Colorectal DSA content
The specific content (23,089 probesets) of the Colorectal
DSA was investigated to assess which groups of probe-
sets predominated following detection +/- differential
expression filtering. When the specific content was
assessed without any filtering applied, 11,320 (49.02%)
probesets were in the sense orientation, 9,754 (42.25%)
probesets were in the antisense orientation and 2,015
(8.73%) had no orientation assigned (Figure 2A). Follow-
ing detection filtering in the sensitive experiment, 771
(47.5%) probesets were in the sense orientation, 816
(50.28%) were in the antisense orientation and only 36
(2.22%) had no orientation assigned (Figure 2B). Finally,
102 (53.68%) probesets were in the sense orientation
and 88 (46.32%) probesets were in the antisense orienta-
tion following detection plus differential expression fil-
tering in the sensitive experiment (Figure 2C). Similar
results were obtained for the resistant experiment
(Additional File 6).
Due to the predominance of probesets in antisense
orientation following filtering in the sensitive and resis-
tant experiments, and the fact that little is known about
the functionality of these ‘antisense’ transcripts we chose
to investigate them further. Starting with the sense pro-
besets and antisense probesets, we isolated only those
with corresponding Unigene ID and removed the probe-
sets with redundant Unigene IDs. Out of the 6,073
sense probesets and 5,324 antisense probesets 2,456
were in sense:antisense (SAS) pairs. In the sensitive
experiment, following detection filtering, 45 probesets
were matched SAS pairs, with 661 antisense probesets
and 638 unique sense probesets. Following detection
and differential expression filtering in the sensitive
experiment, 9 probesets were matched SAS pairs, with
234 antisense probesets and 267 sense probesets
(Table 4). Similar results were found for the resistant
experiment (Table 4). Overall, for the sensitive experi-
ments, up to 7% of the sense and antisense probesets
existed in SAS pairs, while up to 9% of the sense and
antisense probesets existed in SAS pairs in the resistant
experiment.
Sense:Antisense (SAS) probe pair analysis
In vitro analysis
Of the 1299 Colorectal DSA-specific probesets detected
in this experiment, 661 were in the antisense orientation
and 638 were in the sense orientation, and 45 were
common to both sense and antisense probesets and
termed SAS probe pairs (Additional File 6). Gene ontol-
ogy analysis revealed that the SAS probesets were
involved in a plethora of biological processes, of those
the most statistically robust terms were oxidative phos-
phorylation, JAK-STAT signaling, phosphorylation,
metabolism, cell death and splicing (data not shown).
We then chose two SAS probesets randomly from the
list of 45 as exemplars for sequence alignment, which
were SOCS6 and IGF2BP2. We aligned the full length
sequences of the sense and antisense probesets to the
h u m a ng e n o m ev i at h eE N S E M B Lw e b s i t e .T h ef u l l
Table 2 Pathway analysis from Plus2.0 array
Pathways Number of genes p value
Aminoacyl-tRNA biosynthesis 18 1.50×10
-07
Cell cycle 47 6.67×10
-05
Folate biosynthesis 19 2.44×10
-06
Glycerophospholipid metabolism 19 0.0158
Oxidative phosphorylation 25 0.0176
Purine metabolism 50 2.86×10
-07
Pyrimidine metabolism 33 6.26×10
-07
Starch and sucrose metabolism 21 0.000845
Ubiquitin mediated proteolysis 21 0.00116
Wnt signaling pathway 42 0.0453
Based on the complete content of the Plus2.0 array for 3296 genes passing
flags, 1.3-fold change and t-test in the sensitive experiment. Displayed are the
numbers of genes from a given pathway that are detected, differentially
expressed and also passing a t-test filter. Pathways selected that are
statistically significant based on hypergeometric statistics.
Table 3 Pathway analysis from Colorectal DSA
Pathways Number
of genes
p value
Biosynthesis of steroids 17 1.26×10
-07
Cell cycle 50 1.24×10
-05
DNA polymerase 16 0.000153
Fatty acid metabolism 17 0.0119
Folate biosynthesis 18 0.000637
Fructose and mannose metabolism 18 0.00818
Glycerophospholipid metabolism 21 0.0271
Glycolysis Gluconeogenesis 17 0.00872
Insulin signaling pathway 44 0.0427
Oxidative phosphorylation 46 2.98×10
-09
Proteasome 15 1.50×10
-08
Purine metabolism 59 8.06×10
-07
Pyrimidine metabolism 43 3.15×10
-08
Starch and sucrose metabolism 26 0.000391
Tryptophan metabolism 27 0.00542
Valine, leucine and isoleucine degradation 19 0.00915
Based on the complete content of the Colorectal DSA for 3713 genes passing
flags, 1.3-fold change and t-test in the sensitive experiment. Displayed are the
numbers of genes from a given pathway that are detected, differentially
expressed and also passing a t-test filter. Pathways selected that are
statistically significant based on hypergeometric statistics.
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Page 6 of 14length sequence for the SOCS6 sense probeset aligns
exactly with the SOCS6 gene, while the full length
sequence of the antisense probeset for SOCS6 is located
on the reverse strand of SOCS6 and shows clear
sequence overlap with the full length SOCS6 sequence
(Figure 3A). The second SAS probeset that was chosen
for further analysis was IGF2BP2. Again, we aligned our
full length sense and antisense sequences to the human
genome and found that the sense IGF2BP2 full length
sequence aligned exactly with the IGF2BP2 gene, which
was located on the reverse strand. In addition, our anti-
sense full length sequence was located on the forward
Sense
53.68%
Antisense
46.32%
A. B.
C.
Sense
49.02%
Unassigned
8.73%
Antisense
42.25%
Sense
47.50%
Unassigned
2.22%
Antisense
50.28%
Figure 2 Colorectal DSA-specific probeset analysis. Pie charts displaying the Colorectal DSA-specific (unique) content (probesets) breakdown
for the 5-FU sensitive experiment. A. Total Colorectal DSA-specific content breakdown. B. Based on detected probesets. C. Based on detection +
differential expression.
Table 4 Sense and antisense in vitro analysis
DSA-specific probesets Sense Antisense SAS pairs
All probesets 6073 5324 2456
Sensitive experiment Detection 638 661 45
Resistant experiment Detection 724 760 68
Sensitive experiment Detection + DE 267 234 9
Resistant experiment Detection + DE 215 223 8
Table displaying the number of genes (DSA-specific) in the sense and
antisense orientation for the 5-FU sensitive and resistant in vitro experiment.
Also displayed is the total number of probesets that are represented in both
the sense and antisense orientation (SAS pairs). All analyses include genes
identified from detection +/- differential expression filtering. Acronyms used:
DSA: Disease-specific array, SAS: sense:antisense pairs, Detection: probesets
passing Affymetrix flag calls, DE: differential expression.
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f u l ll e n g t hs e n s es e q u e n c e( F i g u r e3 B ) .T h eo c c u r r e n c e
and more importantly, the altered expression of these
SAS pairs would suggest that the antisense sequences
m a yh a v es o m ef u n c t i o n a lr o l ei nt h i sd i s e a s es e t t i n g ,
which may be in gene regulation.
Clinical analysis
Due to the high level of Colorectal DSA probesets
observed in the antisense orientation and given the
results obtained from the in vitro analysis (Table 4) we
wanted to assess if there were similar levels of antisense
expression in clinical colorectal tumour samples, and in
addition, if any of these probesets were expressed in
SAS pairs. Microarray profiling was carried out on 28
pre-treatment (Irinotecan/5-FU) metastatic biopsies
using the Colorectal DSA. In this analysis, the annotated
probesets from the specific content of the Colorectal
DSA were isolated for further examination. It was
observed that, following detection filtering, 265 probe-
sets occurred in the sense orientation, 168 probesets
occurred in the antisense orientation and 8 probesets
existed in SAS pairs (Table 5). In addition, following
detection and differential expression filtering, 87 probe-
sets occurred in the sense orientation, 67 probesets
occurred in the antisense orientation and 3 occurred in
SAS pairs (Table 5). Interestingly, the analysis from the
pre-treatment metastatic biopsies demonstrated that
there is a high incidence of antisense expression in clini-
cal samples and furthermore, that up to ~5% of these
occur in SAS pairs suggesting a potential functional role
and in addition, clinical relevance of these SAS pairs. Of
note, one of the SAS pairs identified from the pre-
A.
B.
SOCS6
ADXCRI H. 3982. C1 _x_at
ADXCRSS. Hs#S1 869280_at
q27.2
IGF2 B P2
ADXCRPDRC. 9501 . C1 _at
ADXCRPD. 9501 . C1 _at
Figure 3 Genomic alignments. Genomic alignments for two of the SAS pairs represented on the Colorectal DSA and passing detection filtering
in the 5-FU sensitive experiment. Sequences aligning to the sense strand of the genome appear in the upper half of the images while
sequences aligning to the antisense strand of the genome appear in the lower half. A. Alignment of the DSA sequences corresponding to the
SOCS6 gene. B. Alignment of the DSA sequences corresponding to the IGF2BP2 gene.
Table 5 Sense and antisense clinical analysis
DSA-specific probesets Sense Antisense SAS pairs
All probesets 6073 5324 2456
Detection 265 168 8
Detection + DE 87 67 3
Table displaying the number of genes (DSA-specific) in the sense and
antisense orientation for the pre-treatment metastatic CRC biopsies. Also
displayed is the total number of genes that are represented in both the sense
and antisense orientation (SAS pairs). All analyses include genes identified by
detection +/-differential expression filtering. Acronyms used: DSA: Disease-
specific array, SAS: sense:antisense pairs, Detection: probesets passing
Affymetrix flag calls, DE: differential expression.
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Page 8 of 14treatment metastatic biopsies was also identified from
the in vitro analysis (both 5-FU-sensitive and -resistant
experiments), the probeset coded for the IGF2BP2 gene.
When comparing the probesets in the sense orienta-
tion, antisense orientation and those that exist in SAS
pairs, it was observed that 244 sense probesets are com-
mon between the sensitive in vitro and clinical experi-
ments, while 247 sense probesets are common between
the resistant in vitro and clinical experiments and 565
sense probesets were found to be common between the
sensitive and resistant in vitro experiments. Further ana-
lysis demonstrated that 147 antisense probesets were
shared between the sensitive in vitro and clinical experi-
ments, 150 antisense probesets were common between
the resistant in vitro and clinical experiments, while 582
antisense probesets were common between the sensitive
and resistant in vitro experiments. Finally, in terms of
those probesets that were detected as SAS pairs, 7 were
common between the sensitive in vitro and clinical
experiments, 5 SAS pairs were shared between the resis-
tant in vitro and clinical experiments and 34 SAS pairs
were common between the sensitive and resistant in
vitro experiments (Additional File 7).
Discussion
The aim of this study was to compare transcriptional
profiling data generated from colorectal cancer cell lines
following treatment with 5-FU using either a leading
generic genomic-based microarray (Plus2.0 array) or a
disease-specific transcriptomic-based microarray (Color-
ectal DSA). The Colorectal DSA was developed based
on the colorectal transcriptome, which was generated
from large-scale in-house sequencing, public data
mining and experimental investigation [32]. The DSA
array is a transcriptome based array as opposed to the
Plus 2.0 which a genomic based array. Given the greater
complexity of the transcriptome in comparison to the
genome, it would be expected that an array of this type
would detect a greater number of transcripts. When
comparing the Colorectal DSA to the Plus2.0 array, the
Colorectal DSA contains 37.5% unique information
(23,089 probesets), which is not contained on the
P l u s 2 . 0a r r a ya n dt h ea i mo ft h ec u r r e n ts t u d yw a st o
assess how important this unique information is. One of
the benefits of the Colorectal DSA is that it is also
based on the Affymetrix GeneChip technology meaning
that cross-platform comparisons are possible.
The same experimental design was used for each
microarray study, consisting of parental or 5-FU-resis-
tant HCT116 cells either untreated or treated with 5-FU
for 24 h. The resultant expression profile generated
from the parental cells following treatment with 5-FU
w a st e r m e da st h es e n s i t i v ee x p e r i m e n t ,w h i l et h e
expression profile generated from the resistant cells
following 5-FU was termed as the resistant experiment.
To assess the performance of each microarray platform
we compared the complete content (all probesets) of the
arrays based on detection (Flags, present or marginal)
and detection plus differential expression.
Following analysis of the complete content of the
microarrays, the Colorectal DSA outperformed the
Plus2.0 array in terms of probesets detected and
detected plus differentially expressed and also displayed
a lower variance between sample replicates. In addition,
the Colorectal DSA identified more pathways in both
the sensitive and the resistant experiments when com-
pared to the Plus2.0 array and also identified common
pathways important for drug response and also drug
resistance, cell cycle, insulin signaling, purine metabo-
lism and pyrimidine metabolism. Indeed, it is not
surprising that cell cycle, purine and pyrimidine metabo-
lism pathways were altered following 5-FU treatment in
sensitive and 5-FU-resistant cells given the mechanism
of action of the drug. Interestingly, insulin signaling was
also altered following 5-FU treatment in both sensitive
and resistant settings. Previous studies have demon-
strated that insulin signaling has an important role in
colorectal cancer progression [33,34]. Dallas et al
demonstrated that colorectal cancer cells that are resis-
tant to 5-FU and oxaliplatin, by repeated exposure to
drug, are more responsive to IGF-1R inhibition than the
parental cells [35], suggestingt h a ti n s u l i ns i g n a l i n gi s
deregulated during the process of acquiring drug resis-
tance. There are a number of reasons that can account
of the observed differences in pathway identification
between the two platforms, firstly, in terms of the ‘com-
plete’ probeset analysis, the Colorectal DSA detected
more probesets and also more differentially expressed
probesets than the Plus2.0 array. More importantly, in
terms of those probesets that are unique to each array
platform our analysis suggested that the Plus2.0 array
detected more probesets than the Colorectal DSA. In
terms of pathway analysis we are interested in specific
genes, so when we assessed the percentage of probesets
t h a tc o d e df o ras i n g l eg e n en a m e ,w ef o u n dt h a tt h e
Colorectal DSA identified many more individual genes
than the Plus2.0 array, which identified multiple probe-
sets that coded for the same gene name. Overall, this
suggests that the Colorectal DSA was identifying more
differentially expressed ‘unique’ genes than the Plus2.0
array and this accounts for the observed differences in
pathway identification between the two array platforms.
We also wanted to examine the microarray specific
content of the Colorectal DSA, which was not present
on the Plus2.0 array. We found that approximately 50%
of the Colorectal DSA specific probesets are in the anti-
sense orientation, which is much higher than expected.
Upon further examination of the microarray-specific
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Page 9 of 14probesets, we demonstrated that some are expressed in
either the sense or antisense orientations only, while a
portion (up to 8.9%) are detected in sense:antisense
(SAS) pairs. Recently, the publication of the ENCODE
pilot project, which aimed to provide a detailed charac-
terization of 1% of the human genome, demonstrated
that there is a much higher level of transcription than
originally thought and this includes the generation of a
high number of non-protein encoding transcripts [36].
In addition, the literature suggests that approximately
20% of human protein-encoding genes have an asso-
ciated natural antisense transcript (NAT), however,
recent studies suggest that this figure could be much
higher [23,37-40]. NATs can be divided into either cis-
acting or trans acting in nature [41]. Cis-acting NATs
are transcribed from the opposing DNA strand at the
same genomic locus, while trans-acting NATs are tran-
scribed from separate loci. The cis-NATs can also be
further categorized according to their relative orienta-
tion and degree of overlap, either 5’ to 5’ (head to head),
3’ to 3’ (tail to tail) or fully overlapping [37,41]. NATs
have been proposed to regulate the expression of their
target genes at several levels, but as yet no experimental
data has been provided to assign a definite function to
N A T s .H o w e v e r ,s o m es t u d i e su s i n gR T - P C R ,n o r t h e r n
blotting or microarray profiling have validated the
expression of antisense transcripts [23,38,39,42]. Inter-
estingly, some SAS pairs are flanked by the same tran-
scription factor binding sites, suggesting that the SAS
pairs may be co-regulated [41]. Analysis has demon-
strated that SAS pairs can display concordant expression
patterns, or discordant expression patterns [37]. In addi-
tion, studies have demonstrated that targeting an anti-
sense transcript using a siRNA approach can alter the
levels of the sense transcript, by either up-regulating
sense transcription or down-regulating sense transcrip-
tion [40,43], so the results are not always as expected.
However, the same studies have demonstrated that
alterations of the sense transcript does not affect the
antisense expression levels [40,43].
As previously described, the functional role of these
antisense transcripts is currently unknown, but they
have been implicated in transcriptional and translational
interference, RNA masking, dsRNA-dependent mechan-
isms, alternative splicing, stability, cellular transport and
chromatin remodeling [37,40,41,44]. However, the func-
tional relevance of antisense transcripts is something
that is now commonly accepted [45-47]. Studies have
demonstrated that long antisense transcripts function as
epigenetic regulators of transcription in human cells
[46]. In addition, studies that have validated the func-
tional relevance of antisense transcripts suggest that
they are not a uniform group of regulatory RNAs, but
rather that they carry out a wide variety of biological
roles [47]. The utility of a transcriptome-based approach
has been demonstrated in the detection of these non-
coding antisense transcripts, as this information could
be important when examining pathway regulation.
Further examination of these NATs may answer a num-
ber of important questions such as why when an
upstream regulator of a pathway is highly up regulated
at the mRNA level do we not see downstream mediators
up regulated, or why do the changes observed at the
RNA level not always correlate with protein expression?
Obviously, a great deal of experimental work would
need to take place to assess whether NATS do play a
role in gene regulation, but if as we suspect at least
some do, we need to not only examine the sense tran-
scripts, but also the antisense transcripts at the same
time to get a true view of what is happening in the cell,
for example, following drug treatment.
We further examined the 45 SAS pairs that were
detected as either present or marginal in the 5-FU sensi-
tive experiment; we decided not to include a fold change
filter at this stage as it is not necessarily to have both
the sense and the antisense transcript altered to a cer-
tain level to see a functional effect. For example, the
antisense may be up regulated which leads to the sup-
pression of the sense, resulting in no change in the
sense probeset. Overall, when we examined the intensi-
ties/expression of the probesets contained within the
SAS pairs it was found that ~50% displayed similar
intensities, therefore displaying no differential intensities
between sense and antisense probesets. However, ~50%
displayed discordant or differential intensities, therefore
this group of SAS pairs may be the most functionally
relevant, however, this will require more experimental
testing. Gene ontology analysis demonstrated that these
SAS pairs were involved in diverse biological processes,
with the most statistically robust involved in oxidative
phosphorylation, JAK-STAT signaling, phosphorylation,
metabolism, cell death and splicing. We further chose
two SAS pairs to examine at the sequence level, they
were SOCS6 and IGF2BP2. Sequence alignment demon-
strated that the full length SOCS6 transcript aligned
exactly with the SOCS6 gene on the forward strand of
chromosome 18. In addition, the full length antisense
transcript aligned to the reverse strand of chromosome
18 and demonstrated good tail to tail sequence overlap
with the full length sense sequence and the SOCS6
gene. In terms of IGF2BP2, the full length sense
sequence aligned completely with the IGF2BP2 gene on
the reverse strand of chromosome 3. The full length
antisense sequence aligned to the forward strand of
chromosome 3 and again demonstrated good tail to tail
overlap with the full length sense sequence and the
IGF2BP2 gene. The sequence alignment results demon-
strate that the SAS pairs show good overlap in sequence
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the opposing DNA strand in the same genomic locus.
Numerous novel SAS pairs have previously been identi-
fied on DSA microarrays and their existence validated
with alternative technologies including strand-specific
RT-PCR. Functional relevance has also been suggested
through analysis of SAS pair expression patterns [48].
Full characterization of the IGF2BP2 and SOCS6 anti-
sense transcripts will require further work which forms
the basis of future studies however; inspection of the
sequences with the Ensembl Human Genome Browser
supports their existence. Extensive EST evidence exists
and appears to suggest a regular exonic structure.
Numerous currently unclassified regulatory elements
also occur in the region surrounding the sequences.
Since both the EST sequencing used in DSA design and
the experimental labelling process are polyA-based, it
would suggest that the transcripts are polyadenylated,
but since the ESTs represent only a fragment of the full
transcript, analysis of precise polyA signal location and
constitution (i.e. canonical or non canonical) is difficult.
To investigate the clinical relevance of SAS pairs we
utilized microarray data generated from pre-treatment
(irinotecan/5-FU) metastatic colorectal biopsies with full
response data. Following detection filtering we demon-
strated that 8 SAS pairs existed (4.8% of total antisense
and 3% of total sense probesets). In addition, we demon-
strated that 3 SAS pairs existed following detection plus
differential expression filtering (4.5% total antisense and
3.4% total sense probesets). Upon examination of the
probesets in the sense orientation, antisense orientation
and those existing in SAS pairs between in vitro experi-
ments and clinical experiments, the results demonstrate
that there is a high percentage of sense, antisense and
SAS pairs that exist between in vitro and clinical sam-
ples. The clinical experiments generated fewer sense,
antisense and SAS pairs than the in vitro experiments,
however, a high percentage of those detected in the
clinical experiment were also detected in the in vitro
experiments. Taken together, these results suggest that
in vitro experiments do highlight potentially clinically
relevant information; however, these types of analysis
would require further independent validation. These in
vitro and clinical analyses demonstrate in this disease
setting that potentially up to 8.9% of all probesets could
exist in SAS pairs; currently there is little investigation
to the functional role that these SAS pairs may play.
Interestingly, one SAS pair, IGF2BP2,w a sf o u n dt ob e
common between the in vitro and the clinical analysis.
IGF2BP2 has been demonstrated to regulate translation
of IGF2 by binding to its 5’UTR [49]. In addition, IGF2
is known to be overexpressed in cancer [50,51] and spe-
cifically, insulin signaling has been demonstrated to play
a role in colorectal cancer [35,52-55]. Given the results
from the pathway analysis also identifying the signifi-
cance of insulin signaling, further experimental investi-
gation into the identified SAS pairs, in particular
IGFBP2, should discover if some or all have functional
relevance in this disease setting and whether they are
disease-specific or have more widespread effects. The
focus of future studies examining the SAS pairs identi-
fied from this study will also include questions such as
what is their exact function within the cell, are they all
functioning in the same way in this disease setting or is
it dependent on the specific SAS pair.
One of the limitations of this analysis is that we com-
pared the power of the two microarray platforms using
data generated from a single 5-FU-sensitive and -resis-
tant cell line model. While the main focus of the study
was to directly compare the data generated from the
two microarray platforms based on detected transcripts
and pathways and for this a single model cell line would
be appropriate, however, a secondary aim was to assess
the biological relevance of the colorectal transcriptome
and compare this to a generic genomic approach. In this
respect the use of a number of CRC cell line models
would have given greater insight into the power of such
an approach as the problem of tissue homogeneity
would have been addressed to some degree. It is widely
accepted that cell lines models are not very representa-
tive of the primary tumour and to somewhat address
these issues we identified the unique biological informa-
tion, SAS pairs, that was generated using the colorectal
transcriptome-based approach and assessed if these
occurred in metastatic (liver) CRC patient biopsies. The
cell line models identified 45 SAS pairs and when we
examined the data generated from the clinical biopsies
we found that not as many SAS pairs existed, 8 in total
were detected. When we compared the SAS pairs from
the cell lines and patient biopsies we found that 7 were
in common, therefore ~87% of the clinical SAS pairs
were also contained within the cell line SAS pairs list.
This would suggest that many of the cell line SAS pairs
are lost in the clinical samples probably due to the
homogeneity of the cell line model and that those are
occurring in the clinical samples may be the most biolo-
gically relevant, however, further analysis of these SAS
pairs would be required.
Conclusions
In conclusion, we have carried out transcriptional profil-
ing using the Plus2.0 array and the Colorectal DSA and
compared their overall performance. We observed that
the transcriptome-based Colorectal DSA has outper-
formed the genome-based Plus2.0 array as demonstrated
by the detection and differential expression of the entire
microarray content. This study has demonstrated that
the strength of a disease-specific transcriptome-based
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mation gained, as noted from the pathway analysis.
When analyzing the results from the Colorectal DSA a
number of pathways, cell cycle, insulin signaling, purine
metabolism and pyrimidine metabolism, were high-
lighted as important regulators of drug response and
drug resistance, which were not identified using the
Plus2.0 array. In addition, the novel biologically relevant
information gained from the Colorectal DSA contained
a number of antisense probesets that exist in SAS pairs,
including IGF2BP2, again highlighting the potential
importance of insulin signaling, also highlighted by
pathway analysis. It is currently unclear at this point
what the functionality of the identified NATs is, but the
literature suggests that they may be involved in diverse
gene regulatory mechanisms. However, it is clear from
the numbers of antisense probesets detected and differ-
entially expressed by the Colorectal DSA that these may
be very important regulatory transcripts. Finally, if this
disease-specific transcriptome-based approach was not
utilized in this setting, important biologically relevant
information, including the regulation of SAS pairs could
potentially be overlooked.
Additional material
Additional file 1: A. Microarray experimental design. HCT116 parental
and 5-FU-resistant daughter cells were either untreated or treated with
an IC50 dose (of parental) of 5-FU for 24 h. All microarrays were run in
triplicate (biological replicates) on the Plus2.0 array and the Colorectal
DSA. The sensitive experiment is defined as those transcriptional changes
following 5-FU treatment in the parental setting, while the resistant
experiment is defined as those transcriptional changes following 5-FU in
the 5-FU-resistant setting.
Additional file 2: Quantitative RT-PCR primer sequences for
Colorectal DSA microarray validation.
Additional file 3: Graphs showing microarray results and
quantitative RT-PCR validations for 13 genes selected from the
Colorectal DSA. All data was log transformed and the Pearson’s
correlation calculated for (A) the parental HCT116 cells following
treatment with 5-FU for 24 h and (B) the basal comparison between the
HCT116 parental and the 5-FU-resistant sub line. All experiments were
carried out in triplicate (biological replicates).
Additional file 4: Pathway analysis based on the resistant
experiment for the complete content of the Plus2.0 array and the
Colorectal DSA. In the Plus2.0 array experiment 564 genes pass flags,
1.3-fold change and t test filtering in the resistant experiment. In the
Colorectal DSA experiment 1660 genes pass flags, 1.3-fold change and t
test filtering in the resistant experiment. Pathways selected that contain
more than 10 genes per pathway.
Additional file 5: Table displaying the 45 SAS pairs that were
identified from the sensitive experiment following detection
filtering. Displayed is gene name, Unigene ID, Entrez gene ID and gene
description.
Additional file 6: Pie charts displaying the Colorectal DSA-specific
(unique) content (probesets) breakdown for the 5-FU-resistant
experiment. A. Based on detected probesets. B. Based on detection +
differential expression.
Additional file 7: Table displaying the number of detected sense,
antisense and SAS pairs, from the DSA unique content, that are
common between the sensitive and resistant in vitro experiments,
the sensitive in vitro and clinical experiments and the resistant in
vitro and clinical experiments.
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